LBPO.IM01 · 免疫学 · Late-Breaking
增殖性炎症性萎缩中的前列腺腔上皮细胞表现出促炎的先天免疫信号激活,而这在前列腺腺癌中不存在
Prostatic luminal epithelial cells in proliferative inflammatory atrophy display proinflammatory innate immune signaling activation that is absent in prostatic adenocarcinoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
持续的促炎信号驱动多个器官系统的癌症发生。我们曾提出,慢性炎症可能通过增殖性炎症性萎缩(PIA)驱动前列腺癌的发展。PIA病变似乎由炎症损伤和再生所致,其中一小部分直接与高级别前列腺上皮内瘤变(PIN)融合,有时还与早期浸润性腺癌融合。一部分PIA腔上皮细胞(Lu-PIA)表现出PIN和浸润性癌病变所特有的分子特征(PMID:39198404, 34341114)。我们假设,许多Lu-PIA细胞代表了基底细胞与成熟腔细胞之间的一种中间细胞状态(PMID 39198404),并与“前列腺club样细胞”表现出重叠的基因表达(PMID 39198404)。
我们此前通过对根治性前列腺切除标本进行迭代多重免疫组化(STING、NaKATPase、p63、Ki67、NKX3.1、AR、GSTP1、CD45、CK903、CK8)显示,STING在Lu-PIA中升高(AACR AM 2024:摘要LB324)。在此,我们增加了更多样本,对全切片扫描进行解卷积和融合,分割为感兴趣区域(ROIs),表型上分离为基底细胞和腔细胞,并在诊断正常(n=13)、PIA(n=14)、PIN(n=9)、ATRMerge(n=6)、尿道(n=3)和癌区域(n=10)中分别进行分析。融合图像使用HALO(Indica Labs)配合经训练的AI分类器进行分析,实现基底细胞和腔细胞的表型分离(共鉴定出65840个基底细胞和288644个腔细胞)。
基底细胞和Lu-PIA细胞对STING呈强阳性,而正常、原发性前列腺腺癌和PIN腔细胞呈阴性。使用UMAP,Lu-PIA细胞以无偏方式与正常基底细胞和腔细胞分开聚类。此外,RIG-I(STING表达的潜在上游调控因子)和MX1(一种干扰素诱导蛋白,是STING活性的潜在下游激活信号)在PIA腔细胞中升高,而在PIN和腺癌中较低。
我们假设,Lu-PIA细胞中升高的STING、RIG-I和MX1蛋白水平代表了在具有基底与腔之间中间表型的细胞中发生的一种内在先天免疫应答。这导致或有助于维持慢性炎症和促炎信号,从而引起细胞损伤和再生、DNA损伤及随后的体细胞改变(如致癌突变)以及表观遗传改变。在罕见的发生体细胞改变的细胞中,这种内在先天免疫应答的沉默可能发生,从而允许MYC表达和活性增加、AR信号增加,并演变为肿瘤性PIN和/或癌细胞。肿瘤性腔细胞中减弱的先天免疫信号可能有助于解释前列腺癌在免疫学上呈“冷”的这一观察结果。
查看英文原文 English abstract
Sustained proinflammatory signaling drives cancer initiation in multiple organ systems. We have postulated that chronic inflammation may drive prostatic cancer development through proliferative inflammatory atrophy (PIA). PIA lesions appear to result from inflammatory injury and regeneration, and a small subset merges directly with high grade prostatic intraepithelial neoplasia (PIN) and at times early invasive adenocarcinoma. A subset of PIA luminal epithelial cells (Lu-PIA) display molecular features characteristic of PIN and invasive carcinoma lesions (PMIDs: 39198404, 34341114). We hypothesized that many Lu-PIA cells represent an intermediate cell state between basal and mature luminal cells (PMID 39198404) and show overlapping gene expression with “prostatic club-like cells” (PMID 39198404).
We previously showed that STING was increased in Lu-PIA using iterative multiplex IHC (STING, NaKATPase, p63, Ki67, NKX3.1, AR, GSTP1, CD45, CK903, CK8) on radical prostatectomies (AACR AM 2024: Abstract LB324). Here, additional samples were added and whole-slide scans were deconvoluted and fused, segmented into regions of interest (ROIs), phenotypically separated into basal and luminal cells, and analyzed separately across diagnostically normal (n=13), PIA (n=14), PIN (n=9), ATRMerge (n=6), urethra (n=3), and cancer regions (n=10). Fused images were analyzed using HALO (Indica Labs) with trained AI classifiers, allowing phenotypic separation of basal and luminal cells (65840 basal and 288644 luminal Cells Identified).
Basal and Lu-PIA cells were strongly positive for STING, while normal, primary prostatic adenocarcinoma, and PIN luminal cells were negative. Using UMAP, Lu-PIA cells clustered in an unbiased manner separately from normal basal and luminal cells. Furthermore, RIG-I, a potential upstream regulator of STING expression, and MX1, an interferon-induced protein that is a potential downstream activation signal of STING activity, were elevated in PIA luminal cells and low in PIN and adenocarcinoma.
We hypothesize that elevated STING, RIG-I, and MX1 protein levels in Lu-PIA cells represent an intrinsic innate immune response occurring in cells with an intermediate phenotype between basal and luminal cells. This leads to, or helps sustain, chronic inflammation and proinflammatory signaling leading to cell injury and regeneration, DNA damage and subsequent somatic alterations such as oncogenic mutations, and epigenetic alterations. In rare somatically altered cells, silencing of this intrinsic innate immune response may occur, allowing increases in MYC expression and activity, AR signaling, and evolution into neoplastic PIN and/or cancer cells. The dampened innate immune signaling in neoplastic luminal cells may contribute to the observation that prostate cancers are immunologically cold.
利益披露 Disclosure
T. M. Steele, None..
J. Hicks, None..
Q. Zheng, None..
A. K. Meeker, None..
M. K. Graham, None..
A. Shetty, None..
R. Wang, None..
C. Gomes-Alexandre, None..
F. Caramella Pereira, None..
W. G. Nelson, None..
S. Kachhap, None.
S. Yegnasubramanian,
Bristol-Myers Squibb and Celgene Other, Sponsored Research Support.
Janssen Other, Sponsored Research Support.
Cepheid Sponsored Research Support.
A. M. De Marzo,
Metirra Inc Other, Sponsored Research Support.
AztraZeneca Other, Sponsored Research Support.